This report was first published by Endpoints News. To see the original version, click here
Gilead continues to scale back its long relationship with Arcus Biosciences.
The companies will step away from working on a number of programs together, according to SEC documents, after Gilead declined to pick up an option payment. The decision comes as another Phase 3 study for the TIGIT program domvanalimab was scrapped due to futility. After failing in upper GI cancers last December, domvanalimab failed this time in lung cancer.
您已阅读24%（525字），剩余76%（1655字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。